Our annual survey measures satisfaction with a range of services and activities including our role and performance
Important information regarding fees and charges applicable from 1 July 2018
Safety advisory – Platinum Male Enhancer capsules pose a serious risk to your health and should not be taken.
Safety advisory – Bulbao Male Enhancer tablets pose a serious risk to your health and should not be taken.
Safety advisory – Meltz Instant Energy for Males tablets pose a serious risk to your health and should not be taken.
Changes to Medicine GMP fees and charges will become effective 1 July 2018
ACSS Consortium Generic Medicines Working Group public statement for Brazil meeting, October 2017
A summary of the fees and charges for the financial year 2018-19 is now available
Hazard alert – firmware update to improve battery performance and cybersecurity
End of transition arrangements for orphan drugs designated under the previous program
Interim decisions to amend, or not amend, the Poisons Standard with respect to substances referred to the March 2018 ACMS/ACCS now available
TGA no longer considers it necessary to apply increased audit requirements to particular European notified bodies for medical devices.
ACM meeting statement, meeting 8, April 2018
Electronic submission update – version 3.1 specifications reminder
Consumers and health professionals are advised that rare cases of harm to the liver have been associated with products that contain Camellia sinensis (green tea) extracts.
Product defect alert – potential for blister strip to contain lower strength tablets
The TGA intends to make a small amendment to the eCTD validation criteria
Information on activities within the electronic submissions space
The TGA is currently undertaking work to streamline and automate our electronic dossier receipt system
Consultation on the proposed Schedule 3 substances to be added to Appendix H of the Poisons Standard is now open.